The Australian Department of Health’s Office of Drug Control (ODC) has varied Cann Group’s licences to include its Mildura site, allowing activities to begin at the facility.
Under the new varied licences, Cann Group must provide the ODC with evidence that an independent security assessment has been undertaken on the Mildura site once it has been constructed.
This news comes hot on the heels of the company getting A$50 million in finance approved through NAB’s agribanking division.
Cann Group CEO Peter Crock said: “The variation to our licences will enable us to proceed with certainty in respect of the building of the facility and moving into cultivation, production and manufacture from the facility seamlessly. We are on track to be processing and releasing material from our Mildura facility by the end of the first quarter of calendar year 2022.”
The licences were first re-issued in February 2018, meaning the end period will be in February 2021. Cann Group will be applying for extensions to the licences.
